ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ORX750

A development code.

Its studies are mostly in Idiopathic Hypersomnia, led by Eli Lilly.

Furthest: phase 2, since Dec 23, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly22 open or runningphase 2since Dec 23, 2024Dec 23, 2024Dec 2026phase 2 · NCT06752668

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 2 study in Idiopathic HypersomniaFirst studyNCT06752668 · 248 planned · United States, Canada, France and more
  2. Jul 2, 2025Phase 2 study in Idiopathic HypersomniaNCT07096674 · 90 planned · United States, Canada, Italy and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in Idiopathic HypersomniaNCT06752668

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07096674Idiopathic Hypersomnia · United States, Canada, Italy and more2RecruitingApr 30, 202690
NCT06752668Idiopathic Hypersomnia · United States, Canada, France and more2RecruitingDec 2026248

How it is read

Names in the registry

  • “ORX750”, 4 entries

Codes read as this program: ORX750.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.